ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Scholar Rock Holdings Corporation

Scholar Rock Holdings Corporation (SRRK)

28.15
0.00
(0.00%)
Closed 12 November 8:00AM
0.00
0.00
(0.00%)

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
28.15
Bid
26.61
Offer
29.18
Volume
-
0.00 Day's Range 0.00
6.76 52 Week Range 35.3799
Market Cap
Previous Close
28.15
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
1,889,800
Shares Outstanding
90,257,566
Dividend Yield
-
PE Ratio
-15.33
Earnings Per Share (EPS)
-1.84
Revenue
-
Net Profit
-165.79M

About Scholar Rock Holdings Corporation

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States.... Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States. The company's lead product candidate is SRK-015 which is a highly selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
-
Scholar Rock Holdings Corporation is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker SRRK. The last closing price for Scholar Rock was US$28.15. Over the last year, Scholar Rock shares have traded in a share price range of US$ 6.76 to US$ 35.3799.

Scholar Rock currently has 90,257,566 shares in issue. The market capitalisation of Scholar Rock is US$2.54 billion. Scholar Rock has a price to earnings ratio (PE ratio) of -15.33.

SRRK Latest News

Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin

- Preclinical data show that SRK-439 increased lean mass and lowered fat mass gain in mice receiving metformin - Data support that Scholar Rock’s unique approach to selective myostatin...

Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious...

Scholar Rock to Participate in Upcoming Investor Conferences

Scholar RockΒ (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious...

Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting

Poster presentation to include new safety, efficacy, and biomarker data from the long-term expansion phase of the DRAGON trial in patients with advanced solid tumors treated with SRK-181 Scholar...

Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering

Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders...

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the β€œCompany”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other...

Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants

Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.421.5146051208127.7330.96526.887885034928.89503588CS
4-0.78-2.6961631524428.9331.2426.8878111589829.17759895CS
1218.8201.0695187179.3535.37996.76188980025.97971535CS
2614.72109.60536113213.4335.37996.76136460320.08276865CS
5218.21183.1991951719.9435.37996.76111322918.49795674CS
156-6.31-18.311085316334.4636.434.32568315714.0280982CS
26019.55227.3255813958.6704.32557963720.32679654CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AALAmerican Airlines Group Inc
US$ 14.16
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 66.1494
(0.00%)
0
AADIAadi Bioscience Inc
US$ 2.10
(0.00%)
0
AACGATA Creativity Global
US$ 1.03
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 14.16
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 66.1494
(0.00%)
0
AADIAadi Bioscience Inc
US$ 2.10
(0.00%)
0
AACGATA Creativity Global
US$ 1.03
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 14.16
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 66.1494
(0.00%)
0
AADIAadi Bioscience Inc
US$ 2.10
(0.00%)
0
AACGATA Creativity Global
US$ 1.03
(0.00%)
0

SRRK Discussion

View Posts
Monksdream Monksdream 2 weeks ago
SRRK under $30
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 3 weeks ago
see the share price this week.
The people behind the $ here.... dont get fooled by this.
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
over 60mn shares traded since the news were announced..... A lot of $$$. They are not "wrong"..
I really dont understand were you are coming from... Trial investigators are real and act independently.

This PR was NOT a fake stunt---- I suspect you just have a history with the stock?
πŸ‘οΈ0
bwrbad bwrbad 1 month ago
that not science discussion, what SOC they compared against - standard palliative care or use of current therapeutics. they omitted the latter from inclusion. they know they are miles behind Spinraza Evyrsdi Zolgensma. compared against these SRRK is baby and need to go back to table and design the right Ph4 study. FDA won't look at current data for serious consideration. the PR was a fake stunt to raise two year worth of money cheaply but wolf cry won't work they did the same before. they fooled everyone again.
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
This beats the SOC and will likely replace it for years and thus generate billions in sales. 3 drugs are used for SMA, they generate 3.5bn in sales and one is for infants only. This might get 1bn in sales too.
πŸ‘οΈ0
bwrbad bwrbad 1 month ago
do tell more on the science in complex high level - just wait for next 2 year till they do PH4 and show better efficacy -& less massaged data
πŸ‘οΈ0
bwrbad bwrbad 1 month ago
SRRK Massive ????????????????? scheme
πŸ‘οΈ0
TechandBio TechandBio 1 month ago
The next SRRK?
BFRI 2 Million floating 5 million market cap generating money from 2 FDA approved drugs deep pipeline 60% owned by tutes and insiders Roth gave $16.00 price target a few days ago.Cash flow positive in a few quarters. micro caps are flying lately.

$srrk
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
Why do you make all these claims if you dont understand the science?
The way this absorbed the offering..... should tell you a lot?

"Large bunch of lawsuits in the way" Why? You know trial investigators are real? You cant skew data in a PH3????
πŸ‘οΈ0
bwrbad bwrbad 1 month ago
SRRK tricky pump raised 300M for 10.6M sh dilution in last two day. next going below 7 and a large bunch of lawsuits in the way
πŸ‘οΈ0
bwrbad bwrbad 1 month ago
10.6M sh diluted by SRRK IN one day
πŸ‘οΈ0
bwrbad bwrbad 1 month ago
holy crrrrraaaap
it was mistake to buy the otherday. selling it at a small loss before it goes back to 7s. it would be futile to hold here. obviously it was a institutional and insiders created hype and fraudulent propaganda event.
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
with the insiders cashing in in the high 20s like that, no one believes in new highs
They didnt believe in 30s in the first place?
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
I believe you are right about all that but the market potential.

Results are not optimal, yet this beats the SOC by a mile..... It will take many years (not sure exactly) until there will be another ph3 for SMA let alone we can judge the results.

Total SOC SMA drugs are 4bn in sales combined and this one is going to capture a large chunk of it, i dont know about the infants. This might go to 50 and beyond.

👍️ 1
bwrbad bwrbad 1 month ago
At least a year if at all approvable. srrk management stunt - questionable result and market potential.
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
getting disorderly now.....
enough with the arguing
πŸ‘οΈ0
Invest-in-America Invest-in-America 1 month ago
SRRK: 'Monk' alerted this today --- if ya have WeBull --- at only $10. (WHO grabbed it then?? Did HE grab it??)
πŸ‘οΈ0
Stockexpertpro Stockexpertpro 1 month ago
SOBR 200K Float Moving Fast SRRK Wow
πŸ‘οΈ0
tw0122 tw0122 1 month ago
300% is a nice gain take it no regrets but if doing a daytrade be a lot more careful
πŸ‘οΈ0
Invest-in-America Invest-in-America 1 month ago
SRRK: And $80-per-share coming ANYWAY, despite what anyone on the Planet has to say!! (WOW!!!)



PS: And yet TRUTH-be-told, their "news" was pure STATISTICAL FLUFF!!!
πŸ‘οΈ0
Invest-in-America Invest-in-America 1 month ago
SRRK: As usual, TW, MONSTER DD by ya!!! (And like you just noted, if they PR a little later today about DUMPING more shares to Market to pay their outrageous bills, whelp, TOILET FLUSH in price!!!)
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
short term, yes
longer term, with these results, someone will want to fund it and have a foot in the door.

A lot of offerings in issues with great data are absorbed fairly easily as in WVE as of late. It helps them finish the job.
(CADL might be a better comparison given the move)
πŸ‘οΈ0
tw0122 tw0122 1 month ago
SRRK they will need to do an offering so your ok .. The Company has incurred recurring losses since its inception, including net losses of $115.4 million and $77.3 million for the six months ended June 30, 2024 and 2023, respectively. In addition, the Company had an accumulated deficit of $791.8 million as of June 30, 2024. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates.
πŸ‘οΈ0
georgie18 georgie18 1 month ago
Good for you...I rode it years ago but have been out for a long time...🥳
πŸ‘οΈ0
Invest-in-America Invest-in-America 1 month ago
SRRK: I avoided this puppy, Bro, and now it has just passed JUPITER!!! (Despite its outrageous price!!)
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
historical relief for patients
this EASILY beats Spinraza, Zolgensma(infants), and Evrysdi (1-1.5bn in sales each) in all the scenarios...
πŸ‘οΈ0
Monksdream Monksdream 1 month ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
πŸ‘οΈ0
tw0122 tw0122 1 month ago
1 out of 3 patients aprox. saw some improvement.. current standard of care) at week 52
30.4% of patients receiving apitegromab had >3 point improvement in HFMSE versus 12.5% of patients on placebo
πŸ‘οΈ0
tw0122 tw0122 1 month ago
Open at $35 going to $20 and lower catch a dip .. Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)

Source: Business Wire
Apitegromab met primary endpoint with statistically significant and clinically meaningful improvement in motor function as measured by the gold standard Hammersmith Functional Motor Scale Expanded (HFMSE) for patients with SMA receiving apitegromab versus placebo (current standard of care) at week 52
30.4% of patients receiving apitegromab had >3 point improvement in HFMSE versus 12.5% of patients on placebo
Patients receiving apitegromab demonstrated early motor function improvement compared to placebo from the first measured time point at 8 weeks, benefit observed at 52 weeks as measured by HFMSE
Patients receiving apitegromab experienced clinically meaningful benefit in motor function across all age groups (ages 2-21)
Favorable safety profile in SAPPHIRE consistent with apitegromab’s long-term safety profile observed in the Phase 2 TOPAZ trial with >48 months of treatment experience in SMA patients
Scholar Rock plans to submit a U.S. Biologics License Application and European Union marketing authorisation application in Q1 2025
Scholar Rock to host Investor Call today at 8:00 AM ET
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced positive topline results from the Phase 3 SAPPHIRE clinical trial (NCT05156320) evaluating the efficacy and safety of apitegromab, an investigational muscle-targeted therapy, in patients with SMA.

The study achieved its primary endpoint demonstrating a statistically significant and clinically meaningful improvement for apitegromab versus placebo in motor function as measured by the gold standard HFMSE in SMA patients on chronic dosing of standard of care therapies (either nusinersen or risdiplam). Based upon the similar pharmacological profile of the 20 mg/kg and 10 mg/kg doses of apitegromab, the statistical analysis plan was prespecified to analyze both the combined dose (10 mg/kg and 20 mg/kg) compared to placebo, and 20 mg/kg dose each compared to placebo. Statistical significance is achieved per the prespecified statistical analysis plan (Hochberg multiplicity adjustment) where the p-value (≤0.025) is more rigorous if only one prespecified analysis crosses the statistical significance boundary of ≤ 0.05.

In the main efficacy population (ages 2-12), the mean difference in change from baseline in HFMSE was 1.8 points (p=0.0192) for all patients receiving apitegromab 10 mg/kg and 20 mg/kg (n=106) compared to placebo (n=50). Patients receiving 20 mg/kg of apitegromab (n=53) showed a 1.4 point mean difference compared to placebo (p=0.1149).

The prespecified analysis of the 10 mg/kg dose showed that patients receiving 10 mg/kg of apitegromab (n=53) showed an improvement of 2.2 points (nominal p=0.0121) compared to placebo.
Based upon PK/PD data from the SAPPHIRE trial, similar levels of target engagement were observed for the 10 mg/kg and 20 mg/kg dose groups.
Motor function outcomes were meaningful and consistent across the main efficacy population and in the ages 13-21 exploratory population, favored apitegromab (n=22) compared to placebo (n=10). Thirty percent of patients receiving apitegromab had >3 point improvement in HFMSE versus 12.5% of patients on placebo. Patients receiving apitegromab demonstrated early motor function improvement compared to placebo from the first measured time point at 8 weeks, benefit expanded at 52 weeks as measured by HFMSE. Following trial completion, 98 percent of SAPPHIRE patients (185/188) enrolled in the ongoing ONYX open-label expansion study.

β€œWe are thrilled that apitegromab met the primary endpoint in our Phase 3 SAPPHIRE clinical study. The results clearly demonstrate robust and clinically meaningful improvement in motor function in patients with SMA,” said Jay Backstrom, M.D., MPH, President and Chief Executive Officer of Scholar Rock. β€œAt Scholar Rock, we are working with urgency to deliver the potentially transformative benefits of apitegromab to children and adults with SMA in the US, Europe, and around the world.”

Treatment with apitegromab was well-tolerated across all age groups. There were no clinically relevant differences in the adverse event profile by dose, 10 mg/kg versus 20 mg/kg. No new safety findings were observed in the SAPPHIRE clinical trial; the profile was consistent with that observed in the Phase 2 TOPAZ clinical trial, including an extension study which had over four years of treatment as of the cut-off date. Serious adverse events (SAEs) were consistent with the underlying disease and current standard of care received by patients; no SAEs were assessed as related to apitegromab. There were no study drug discontinuations due to adverse events.

β€œWe are grateful to the families and investigators who participated in our trials. The positive Phase 3 SAPPHIRE trial, along with over 4 years of TOPAZ clinical trial data, clearly demonstrate the potentially transformative benefit of apitegromab to drive clinically meaningful improvements in motor function as measured by HFMSE in a broad SMA population, where motor function would normally be expected to generally decline over time,” said Jing Marantz, M.D., Ph.D., Chief Medical Officer at Scholar Rock. β€œWe look forward to submitting our applications to the FDA and the EMA in Q1 2025.”

The U.S. Food and Drug Administration (FDA) has granted Fast Track, Orphan Drug, and Rare Pediatric Disease designations, and the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Orphan Medicinal Product designations, to apitegromab for the treatment of SMA. The Company plans to submit a U.S. Biologics License Application (BLA) and a European Union marketing authorisation application (MAA) in Q1 2025.

β€œIt’s a great day for people living with SMA and their families. These encouraging trial results mark a critical milestone for the SMA community,” said Kenneth Hobby, President of Cure SMA. β€œDeclining motor function and hopes for reversing losses associated with muscle weakness are significant unmet needs, impacting activities of daily living, from breathing, eating, self-care, to working and social interactions. We need an approved therapy that can support motor function and further improve daily activities for people with SMA.”

Analyses of the full Phase 3 SAPPHIRE data are ongoing, and Scholar Rock plans to present detailed results at an upcoming medical conference in early 2025. Preliminary baseline characteristics from the trial will be presented during a poster presentation at the upcoming 29th Annual Congress of the World Muscle Society on Friday, October 11, 2024, being held in Prague, Czech Republic.

Conference Call Information

Scholar Rock will hold an investor confere
πŸ‘οΈ0
Tom turtles Tom turtles 1 month ago
Um ..higher
πŸ‘οΈ0
Tom turtles Tom turtles 1 month ago
Their is a God ! Thank You....yahooooo
👍 1
Monksdream Monksdream 2 months ago
SRRK under $10
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
SRRK under $10
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
SRRK under $10
πŸ‘οΈ0
retireat40 retireat40 1 year ago
Wow. Now a $7 stock
πŸ‘οΈ0
georgie18 georgie18 3 years ago
SRRK...$34.75...on the 100ma break...:party:
[11:57 AM]
georgie18 β€” 10/29/2021
SRRK...$27.34...Bullish Doji Star Reversal Pattern to the Upside as the Psar flipped Bullish...

Pincher Squeeze in play here...as the MACD Crosses Positive...Looking for a $40 Break/Hold...imo...we shall see...:party:
πŸ‘οΈ0
georgie18 georgie18 3 years ago
SRRK...$28.45...Lets see if we can Break/Hold the Upper Band today...as the Bollie Squeeze sets up here...imo...We shall see...:party:
[4:32 AM]
georgie18 β€” 10/29/2021
SRRK...$27.34...Bullish Doji Star Reversal Pattern to the Upside as the Psar flipped Bullish...

Pincher Squeeze in play here...as the MACD Crosses Positive...Looking for a $40 Break/Hold...imo...we shall see...:party:
πŸ‘οΈ0
georgie18 georgie18 3 years ago
SRRK...$27.34...Bullish Doji Star Reversal Pattern to the Upside as the Psar flipped Bullish...

Pincher Squeeze in play here...as the MACD Crosses Positive...Looking for a $40 Break/Hold...imo...we shall see...

Played this in the spring for nice profits...Back in again on this Pattern...

Chart... https://schrts.co/HtbEtPcc ...
πŸ‘οΈ0
georgie18 georgie18 3 years ago
SRRK...$31.62...on the 50ma Break to the Upside...:party:
[6:26 AM]
georgie18 β€” 05/24/2021
SRRK...$28.75...Took a starter on the Bullish Harami today...:party:
πŸ‘οΈ0
georgie18 georgie18 3 years ago
SRRK...$29.69...in the P/M...https://finance.yahoo.com/news/scholar-rock-presents-topaz-phase-113000823.html ...:party:
πŸ‘οΈ0
stockguard stockguard 3 years ago
We`ll be back to higher highs soon.
πŸ‘οΈ0
georgie18 georgie18 3 years ago
SRRK...$28.75...Took a starter on the Bullish Harami today...CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for apitegromab, a selective inhibitor of myostatin activation, for the treatment of patients with Spinal Muscular Atrophy (SMA). Fast Track designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and get new drugs to patients earlier. Through Fast Track, Scholar Rock is eligible to submit a rolling Biologic License Application (BLA) for apitegromab if relevant criteria are met...
πŸ‘οΈ0
stockguard stockguard 3 years ago
Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy
https://www.businesswire.com/news/home/20210524005771/en/
πŸ‘οΈ0
stockguard stockguard 4 years ago
Scholar Rock weakness overdone after TOPAZ results, says JPMorgan
JPMorgan analyst Anupam Rama noted that Scholar Rock shares are down about 15%, which Rama views as "overdone," after the company announced update 12-month results from the phase 2 TOPAZ study in the treatment of Type 2/3 Spinal Muscular Atrophy. The 12-month data showed relatively consistent functional benefit compared to six-month interim data reported in October, noted Rama, who added that "there were no major concerns" on the safety front. The analyst, who sees the "totality of data as a probability of success increase lever," reiterates an Overweight rating on Scholar Rock shares.
πŸ‘οΈ0
georgie18 georgie18 4 years ago
SRRK...$48.08...Back in on the Bullish Engulfing Candle on the Overbought Retrace...Psar will flip to a Bullish Buy Position this week...

Break/Hold $52 with no topside resistance and we make a run at $75/$100 range on this Blue Skies Chart...imo...we shall see...

Chart..https://schrts.co/wGhsGXPZ

georgie18 Wednesday, 10/28/20 06:38:13 AM
Re: None 0
Post #
3
of 21
SRRK...$34.85...in the PM...on this Blue Skies Chart set up...no topside resistance here...
[6:37 AM]
georgie1808/10/2020
SRRK...$14.22...Hod...just keeps gradually moving up off my $11.29 alert...I think $31 is coming here...we shall see...

πŸ‘οΈ0
georgie18 georgie18 4 years ago
SRRK...$46.91...Looking for the Upper Bollie breakout...on the Pole N Flag Breakout...imo...we shall see...

georgie18 Tuesday, 11/24/20 07:16:17 AM
Re: georgie18 post# 3 0
Post #
19
of 20
SRRK...$41.40...Bullish Pole N Flag Breakout setting up here as the Bollies start to Squeeze here...Looking for $75/$100 move...imo...we shall see...

Chart... http://schrts.co/rzYtEpQt

georgie18 Wednesday, 10/28/20 06:38:13 AM
Re: None 0
Post #
3
of 19
SRRK...$34.85...in the PM...on this Blue Skies Chart set up...no topside resistance here...
[6:37 AM]
georgie1808/10/2020
SRRK...$14.22...Hod...just keeps gradually moving up off my $11.29 alert...I think $31 is coming here...we shall see...
πŸ‘οΈ0
georgie18 georgie18 4 years ago
SRRK...$46.91...on the Upper Bollie Break...
πŸ‘οΈ0
georgie18 georgie18 4 years ago
SRRK...$41.40...Bullish Pole N Flag Breakout setting up here as the Bollies start to Squeeze here...Looking for $75/$100 move...imo...we shall see...

Chart... http://schrts.co/rzYtEpQt

georgie18 Wednesday, 10/28/20 06:38:13 AM
Re: None 0
Post #
3
of 19
SRRK...$34.85...in the PM...on this Blue Skies Chart set up...no topside resistance here...
[6:37 AM]
georgie1808/10/2020
SRRK...$14.22...Hod...just keeps gradually moving up off my $11.29 alert...I think $31 is coming here...we shall see...

πŸ‘οΈ0
JohnQQ JohnQQ 4 years ago
https://finance.yahoo.com/m/9fae2849-74b9-3d45-9293-6540a970693d/2-top-biotech-stocks-from-the.html
πŸ‘οΈ0
JohnQQ JohnQQ 4 years ago
New Seeking Alpha Article
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock